Takeda To Buy U.S. Vaccine Maker Inviragen For Up To $250 Million
This article was originally published in PharmAsia News
Takeda Pharmaceutical said it plans to pay as much as $250 million for Inviragen, a U.S. vaccine maker with a Singapore subsidiary, in part to gain a preventative for dengue infection.
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.